Theratechnologies Resumes Distribution of EGRIFTA SV® in the U.S.

Theratechnologies Inc. has officially resumed distribution of EGRIFTA SV® (tesamorelin for injection) in the United States, ensuring that patients who rely on the treatment once again have access. This follows FDA correspondence allowing the release of two newly manufactured batches, which are now ready for immediate shipment to network pharmacies. The company's commitment to HIV care remains steadfast, with continued cooperation from regulatory authorities to ensure the treatment reaches those in need.

Christian Marsolais, PhD, Senior VP and Chief Medical Officer at Theratechnologies, expressed gratitude for the FDA’s support in facilitating the product's return to market. Meanwhile, the FDA’s review of the Prior Approval Supplement (PAS) for EGRIFTA SV® is still underway, with an expected action date of April 18, 2025. The therapy remains available exclusively in the U.S., reaffirming Theratechnologies' dedication to advancing care for people with HIV-associated lipodystrophy.